Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00585442 · ClinicalTrials.gov registry record · Early Phase 1
Effects of Vitamin D on Renin Expression in Hypertensive Patients
A Early Phase 1 study, sponsored by University of Utah.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
NCT00585442 is a Early Phase 1 study that was terminated before completion, run by University of Utah. The registered enrollment target is 12 participants.
The verdict
NCT00585442, a Early Phase 1 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The cardiovascular effects of vitamin D therapy (in humans) have been documented only in patients with known vitamin D deficiency or hyperparathyroidism (a surrogate marker of inadequate vitamin D activity). It is unknown whether the cardiovascular benefits of vitamin D therapy extend beyond these patients to the general hypertensive population. We propose to directly measure the effect of vitamin D therapy on plasma renin activity (PRA), plasma renin concentration (PRC), renin transcription (in mononuclear leukocytes), and blood pressure in hypertensive (but otherwise healthy) patients in a randomized, controlled, experimental trial. This will be the first study to assess vitamin D receptor (VDR) biological (PRA, PRC, renin mRNA, and polymorphisms) and hypertensive activity in patients without vitamin D deficiency. We hypothesize that vitamin D inhibition of renin transcription will produce significant reductions in PRA, PRC, renin transcription, inflammatory cytokines, SBP, and DBP, with potential variation by VDR genotype. Such a result may prove to be significant in the treatment of hypertension, as even modest blood pressure reductions (5 mmHg) are associated with a 14% reduction in mortality due to stroke, a 9% reduction in mortality due to CHD, and a 7% overall reduction in all-cause mortality.
Interventions
- DRUG Placebo
- DRUG calcitriol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00585442
The ClinicalTrials.gov registry entry for NCT00585442 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00585442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00585442 about?
NCT00585442 is a clinical study titled "Effects of Vitamin D on Renin Expression in Hypertensive Patients". The cardiovascular effects of vitamin D therapy (in humans) have been documented only in patients with known vitamin D deficiency or hyperparathyroidism (a surrogate marker of inadequate vitamin D activity). It is unknown whether the cardiovascular benefits of vitamin D therapy extend beyond these p...
What is the current status of trial NCT00585442?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2007-05. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00585442?
The interventions under investigation include: Placebo (DRUG), calcitriol (DRUG).
Who is sponsoring clinical trial NCT00585442?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.